Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. It operates in one segment, being pharmaceutical research and development.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
stocks
Better times ahead for these cheap ASX shares?
Our analysts think the outlook looks fairly good for these two undervalued and unloved ASX dividend payers.
video
ASX dividend stocks for 2025
With dividend yields at 25-year lows, it's time to rethink ASX stocks for income according to James Gruber.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,699.10 | 57.60 | -0.66% |
| CAC 40 | 8,106.33 | 100.23 | -1.22% |
| DAX 40 | 22,491.87 | 352.63 | -1.54% |
| Dow JONES (US) | 44,378.43 | 177.91 | -0.40% |
| FTSE 100 | 8,700.97 | 65.76 | -0.75% |
| HKSE | 22,944.24 | 32.57 | -0.14% |
| NASDAQ | 20,006.55 | 34.71 | -0.17% |
| Nikkei 225 | 39,164.61 | 105.79 | -0.27% |
| NZX 50 Index | 13,033.36 | 17.76 | -0.14% |
| S&P 500 | 6,116.53 | 13.05 | -0.21% |
| S&P/ASX 200 | 8,419.20 | 61.80 | -0.73% |
| SSE Composite Index | 3,351.54 | 27.05 | 0.81% |